Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients’ treatment

Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients’ treatment

Aim. To study the effect of levilimab or baricitinib in combination with standard therapy (ST) on the incidence of severe viral pneumonia associated with a new coronavirus infection COVID-19. Materials and methods. A multicenter, open-label observational study of the efficacy and safety of levili...

Full description

Bibliographic Details
Main Authors: Alexey I. Khripun, Andrey V. Starshinin, Yulia O. Antipova, Mariana A. Lysenko, Yulia V. Urozhaeva, Olga F. Gavrilenko, Natalya A. Rusantsova, Andrei A. Tyazhelnikov, Elena Yu. Tikhonovskaya, Natalia V. Okolot, Maria V. Sokolova, Daria S. Fomina, Elena N. Simonova, Tatiana S. Kruglova, Anton A. Chernov, Alena I. Zagrebneva
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2022-06-01
Series:Терапевтический архив
Subjects:
levilimab
baricitinib
cytokine storm
viral pneumonia
covid-19
outpatient
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/108789/82903

Internet

https://ter-arkhiv.ru/0040-3660/article/viewFile/108789/82903

Similar Items